Category: Pharma Industry

Amid Record Drugmaker Refunds, No Adverse Audit Findings for Teva

December 7, 2023 Rich Daly, Editor in Chief Views

The final HRSA manufacturer 340B program audit conducted in fiscal year 2023 had no adverse findings for Teva Pharmaceuticals.

The fifth and final fiscal year 2023 manufacturer audit by federal officials recently concluded with no adverse findings. Meanwhile, the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Two Senior GOP Senators Suggest 340B Linked to Generic Drug Shortages

December 7, 2023 William Newton, Associate Editor/Senior Writer Views

Sen. Mike Crapo (R-Idaho), ranking member of the Senate Finance Committee, said penny pricing under 340B warranted “serious scrutiny in the context of generic products.”

Two Republican Senators on an influential committee suggested during a hearing on Tuesday that 340B discounts could contribute to certain [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Four 340B Terminations, Eight Paybacks to Manufacturers in Latest Provider Audit Findings

December 5, 2023 Rich Daly, Editor in Chief Views

Federal auditors determined terminations from the 340B program were required for either covered entity sites or a contract pharmacy of two more 340B providers.

Federal auditors determined terminations from the 340B program were required for either covered entity sites or contract pharmacies of four [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Biogen Adds Drug with Narrow Approval to 340B Contract Pharmacy Restrictions

December 5, 2023 Rich Daly, Editor in Chief Views

Drugmaker Biogen recently added a third drug to its 340B contract pharmacy restrictions for hospitals.

Biopharmaceutical manufacturer Biogen recently expanded its contract pharmacy restrictions for hospitals to a third drug, after that medication garnered a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Arkansas, Novo Nordisk Clash Over Court’s Role in Contract Pharmacy Law Enforcement

December 5, 2023 William Newton, Associate Editor/Senior Writer Views

Novo Nordisk and the Arkansas Insurance Department are at odds over whether a federal district court should intervene in the enforcement of Arkansas' 340B contract pharmacy law.

Novo Nordisk and the Arkansas Insurance Department (AID) are sparring in court over whether a federal district court should hear [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Reforms Needed, Says Former Presidential Candidate, Drug Industry Consultant

December 5, 2023 Rich Daly, Editor in Chief Views

Howard Dean, a former Democratic presidential candidate who has consulted for the drug industry, said the 340B program is in need of reforms.

The 340B program has become “a multibillion-dollar boondoggle for hospital mega-chains” and needs reform, says Howard Dean, a one-time Democratic [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Massachusetts Senate Passes 340B Contract Pharmacy Protections for Certain 340B Grantees, Hospitals

November 28, 2023 William Newton, Associate Editor/Senior Writer Views

Massachusetts lawmakers are expected to vote on Sen. Pavel Payano's (D) 340B PBM nondiscrimination bill Thursday.

Massachusetts state senators this month unanimously passed a healthcare bill that would protect 340B grantees and certain safety net hospitals [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Provides Benefits, Needs Reform, Says Literature Review

November 28, 2023 Tom Mirga, Editor at Large Views

A JAMA Health Network literature review found that the 340B program provides a range of benefits but needs reforms.

The 340B program has provided a range of benefits but also needs reforms, according to a recent review of published [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B’s Footprint in Medicare Part D Is Growing, Study Says

November 28, 2023 Tom Mirga, Editor at Large Views

A JAMA Health Forum study co- authored by Sean Dickson found the 340B program's footprint in Medicare Part D is increasing.

340B covered entities captured nearly half (49.9%) of their 340B-eligible prescriptions billed to Medicare Part D in 2020, up from [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Senate Democrats Seek Drug Pricing Testimony from Three Pharma CEOs

November 28, 2023 William Newton, Associate Editor/Senior Writer Views

Sen. Bernie Sanders (I-Vt.) and 10 Democrats on an influential committee invited the CEOs of three pharma companies to testify at a January hearing.

Senate Democrats on an influential committee invited the CEOs of three major pharmaceutical companies to testify at a January hearing [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live